Latigo Biotherapeutics: A Pain-Relief Powerhouse Emerges

Latigo Biotherapeutics, a clinical-stage biotechnology company from Thousand Oaks, CA, has secured a whopping $135M in Series A funding. Led by Westlake Village BioPartners, this funding will propel the development of non-opioid pain medicines that target pain at its core. With Desmond Padhi, Pharm.D., at the helm as interim CEO, and Nancy Stagliano, Ph.D., as Chair of the board, Latigo Biotherapeutics is set to revolutionize pain management. Their lead program, LTG-001, promises a new era of pain relief with its innovative approach and potential for superior safety and efficacy. Stay tuned for the groundbreaking advancements from this pain-relief powerhouse.